Pre-market trend | Immunovant (IMVT) surged 35% on May 20, can it continue after the breakout?

Yesterday, Immunovant's stock price surged by 35.26%, with a trading volume of USD 663 million, reaching a recent record high, and the market's enthusiasm for this biotech stock was nearly frenzied. The MACD daily line formed a bullish signal above the zero axis, combined with such an astonishing single-day increase and high trading volume, is typically seen as a strong signal for establishing a phase trend reversal. The stock price broke through the consolidation range of the previous weeks, with the 5-day and 10-day moving averages left far behind, indicating an explosive release of short-term bullish momentum. Such a level of volume breakout in the biotech sector often corresponds to significant catalyst-driven events. From an industry perspective, the capital activity in the biotech sector has significantly increased recently, with Roivant Sciences also rising sharply by 14.89% yesterday, as market attention on innovative drug pipelines continues to grow. Immunovant focuses on FcRn antibody therapy, and its clinical progress in autoimmune diseases may be the core driving force behind this surge. Currently, the overall risk appetite in the U.S. stock market is warming up, with the S&P 500 ETF rising by 1.02%, and both the technology and biotech sectors strengthening, providing a favorable external environment for small and mid-cap growth stocks. Although the Federal Reserve's meeting minutes were hawkish, the market chose to pursue growth logic in the short term. Technically, yesterday's massive long bullish line itself constituted a strong short-term support reference, but the 35% single-day increase also indicates that short-term technical indicators are severely overbought. If trading volume quickly shrinks after the market opens today, the probability of a pullback after a high will significantly increase